Disclaime
- Please be advised that the following presentation might include the scope outside of Astellas product labeling and is provided for sharing purposes only. There is no intent to offer recommendations for administering Astellas products in a manner inconsistent with approved labeling.
- Please refer to TFDA-approved indication, dose, administration, contraindication, warning, and frequent adverse events before prescribing.
- Xtandi's indication for mCSPC by country:
- EMA: Metastatic hormone-sensitive prostate cancer (mHSPC) with androgen deprivation therapy.
- FDA: Metastatic castration-sensitive prostate cancer (mCSPC).
- TFDA: Metastatic castration-sensitive prostate cancer (mCSPC) with androgen deprivation therapy.
|
